Bider D, Menashe Y, Goldenberg M, Dulitzky M, Lifshitz A, Dor J
Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
J Assist Reprod Genet. 1996 Sep;13(8):613-6. doi: 10.1007/BF02069638.
The objective of our study was to explore the effect of dexamethasone (DEX), a highly potent, long-acting glucocorticoid, on the treatment outcome of 74 anovulatory women aged 21 to 29 years, with normal gonadotropins, androgen, and prolactin (PRL) serum levels who failed to conceive on antiestrogen therapy.
The patients received human menopausal gonadotropin/human chorionic gonadotropin (hMG/hCG) for ovulation induction. Starting on day 4 of the induced menstruation, hMG was administered in combination with DEX, 0.5 mg at night, or without DEX as an adjuvant treatment. The total amount of gonadotropins used, time required for stimulation, percentage of fertilization, serum estradiol levels, pregnancy rate, cumulative pregnancy rate, and abortions were recorded.
There were no differences in either the cumulative pregnancy rate (54.1% in the DEX group and 52.7% in the untreated group) or the abortion rates (21.7% in the DEX group compared to 20.8% in the untreated group). The other parameters investigated also did not differ significantly between the groups.
The overall results did not support DEX as a clinically useful adjuvant therapy for anovulatory, normoandrogenic patients.
我们研究的目的是探讨地塞米松（DEX），一种高效、长效的糖皮质激素，对74名年龄在21至29岁、促性腺激素、雄激素和催乳素（PRL）血清水平正常、接受抗雌激素治疗后仍未受孕的无排卵女性治疗结局的影响。
患者接受人绝经期促性腺激素/人绒毛膜促性腺激素（hMG/hCG）诱导排卵。从诱导月经的第4天开始，hMG与DEX联合使用，晚上0.5mg，或不使用DEX作为辅助治疗。记录使用的促性腺激素总量、刺激所需时间、受精率、血清雌二醇水平、妊娠率、累积妊娠率和流产情况。
累积妊娠率（DEX组为54.1%，未治疗组为52.7%）和流产率（DEX组为21.7%，未治疗组为20.8%）均无差异。两组间其他研究参数也无显著差异。
总体结果不支持将DEX作为无排卵、雄激素正常患者的临床有用辅助治疗方法。
Zotero 插件